Armistice Capital and Executives Cleared of Fraud in Vaxart Case

Armistice Capital Secures Complete Exoneration in Vaxart Lawsuit

In a major legal win, Armistice Capital LLC and its executives, including founder Steven Boyd and Managing Director Keith Maher, were fully exonerated by a California federal jury. This verdict was returned after a concise deliberation period of less than four hours, bringing closure to accusations of securities fraud and insider trading connected to the class action filed by investors in Vaxart Inc.

The jury's decision comes in the wake of a trial that commenced on April 14 at the U.S. District Court for the Northern District of California, overseen by Judge Vince Chhabria. The plaintiffs had argued that during the COVID-19 pandemic, Armistice allegedly manipulated the market for Vaxart shares using misleading press releases, claiming that this led to the sale of stocks at inflated prices. Furthermore, it was suggested that the defendants were privy to material nonpublic information when making their sales.

Throughout the trial, defense attorney Charles Connolly from Akin Gump Strauss Hauer & Feld LLP emphasized that the plaintiffs’ case relied heavily on selective interpretations of isolated phrases in Vaxart’s press releases. Connolly maintained that the entirety of the released information was accurate, challenging the notion that Armistice or its executives were aware of any sensitive information prior to the press releases being disseminated. He remarked, "A reasonable investor does not just read the headlines," underlining the importance of comprehensive context in evaluating financial communications.

This case, listed as In re Vaxart Inc. Securities Litigation (Case Number 320-cv-05949), originated from stock transactions carried out by Armistice on June 26 and June 29, 2020. These trades followed announcements from Vaxart regarding a manufacturing partnership and its inclusion in the federal Operation Warp Speed initiative designed to accelerate vaccine development. It is noteworthy that Vaxart and several of its executives, cited as co-defendants in the initial complaint, settled the claims against them separately in 2022 for $12 million.

The successful defense team for Armistice Capital also included Joshua A. Rubin, Lillian J. Rand, Stacey H. Mitchell, Kaitlin D. Shapiro, and David M. Giller, all of whom played pivotal roles in dismantling the plaintiffs' arguments during the trial.

In addition to its impact on the parties involved, this verdict sends a significant message to the investment community about the standards that must be met in proving allegations of market manipulation and insider trading. Legal experts suggest that such cases often hinge on the interpretation of specific communications and the context in which they were made, highlighting the necessity for all investors to remain vigilant yet realistic about the disclosures from companies.

As this case concludes, Armistice Capital stands cleared of all accusations, allowing it to refocus on its investment strategies and stakeholder relations. The importance of transparent communication and due diligence in the finance sector continues to resonate deeply following this verdict, as investors navigate the complexities of securities law and market activities related to high-profile companies like Vaxart.